• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

NIHR Oxford Health Biomedical Research Centre

Email Oxford Health BRC
MENUMENU
  • About
    • About
    • Management and core team
    • Our partners
    • Timeline of our key achievements
    • Core facilities
    • Oxford Health BRC Vacancies
    • Contact Us
  • Departments
    • NIHR Oxford Health Clinical Research Facility
    • Brain Health Centre
    • Oxford Precision Psychiatry Lab (OxPPL)
    • Oxford Dementia and Ageing Research (OxDARE)
    • Treatment Resistant Depression Clinic
    • Experimental Medicine and Industry Partnership (EMIP)
  • Research Themes
    • Summary
    • Better Sleep
    • Brain Technologies
    • Data Science
    • Dementia
    • Depression Therapeutics
    • Flourishing & Wellbeing
    • Mental Health in Development
    • Molecular Targets
    • Pain
    • Preventing Multiple Morbidities
    • Psychological Treatments
  • COVID-19 Research
    • Overview
    • News
    • COVID-19 & clinical management of mental health issues
  • News & Events
    • News
    • Training and Events
    • Psychiatry Department Seminars
  • Patients & Public
    • What is Patient and Public Involvement?
    • Key Contacts
    • Shape our research
    • Take part in our research
    • Resources for researchers
    • Resources for the public
    • Patient and Public Involvement Strategy
    • Young people’s involvement
  • EDI
    • Summary
    • Strategy
    • Diversity in Research Group
    • Key Contacts
  • Industry
    • Collaborate with Oxford Health
    • Who Do We Work With?
    • Industry Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Training Hub
You are here: Home / News / Review reports improved transparency in antidepressant drug trials

Review reports improved transparency in antidepressant drug trials

20th January 2022

A new review and meta-analysis, published in the journal PLOS Medicine, indicates that drug companies have increased disclosure of clinical trials of new antidepressants with negative outcomes, that is, trials that fail to show the drug is more effective than a placebo.

This was shown compellingly in a landmark 2008 study published in The New England Journal of Medicine. The new study – an update of the 2008 study conducted by researchers from OHSU, Oxford Health BRC and around the world – shows a trend toward reporting negative trials more transparently.

The study identified 30 clinical trials on four antidepressants approved by the U.S. Food and Drug Administration between 2008 and 2013. According to FDA records, half of these trials (15) were negative. Among these, eight were either unpublished or misrepresented in the scientific literature as positive. The remaining seven – 47% of the negative trials – were transparently reported as negative. While far from 100%, this is an improvement over the 11% figure for older antidepressants, as found in the 2008 study.

Nowadays there is greater awareness of reporting bias in the scientific literature — not only in psychiatry but across all medicine — and there has been a cultural change: What was once standard practice is no longer considered acceptable,” Cipriani said. “Numerous policy changes have been implemented, which have played a major role in bringing about the increase in transparency.

However, we do not have full transparency yet. Researchers, patients and clinicians should not naively accept published research findings at face value.

Co-author Andrea Cipriani, BRC theme lead and Professor of Psychiatry at the University of Oxford

The study focused on antidepressants, but the findings could apply more broadly to other drug classes and other recent studies have suggested a trend toward increased transparency as well.

While the new findings are encouraging, they still hint at a fundamental shortcoming in medicine: A reliance of studies selectively reported in scientific literature, as opposed to the unvarnished results of clinical trials reported to the FDA.

Doctors prescribe based upon what the drug companies choose to publish, which can be a cherry-picked version of the full story, “By hiding negative trial results and selectively publishing only positive results, drugs will look more effective than they actually are. Doctors need to be made aware of all trial results – positive and negative – so they can be fully informed when they prescribe drugs for their patients.

Fortunately, we are seeing progress,” he said. “Negative studies, once a dirty little secret, are now being acknowledged more often. The dark era of opacity appears to be in the rear-view mirror, but much work lies ahead if we are going to see full transparency.

Lead author Erick Turner, M.D., associate professor of psychiatry in the Oregon Health & Science University School of Medicine

Filed Under: News

Primary Sidebar

News Categories

  • News
    • Clinical Research Facility
    • COVID-19 research
      • Children, young people and family mental health
      • COVID-19 and psychiatric diagnosis
      • Online therapies and resources for clinicians
      • Patient and Public Involvement in the pandemic
      • PHOSP COVID
      • Vaccination and vaccine hesitancy
    • Research Themes
      • Better Sleep
      • Brain Technologies
      • Data Science
      • Dementia
      • Depression Therapeutics
      • Flourishing & Wellbeing
      • Mental Health in Development
      • Molecular Targets
      • Pain
      • Preventing Multiple Morbidities
      • Psychological Treatments
    • Training and Development

Footer

Follow us

  • LinkedIn
  • Twitter
  • YouTube

Improving brain health: the future in mind

The National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC) is a partnership between Oxford Health NHS Foundation Trust and the University of Oxford.  We are part of the Oxford Academic Health Partners.
Oxford Academic Health Partners
  • Sitemap
  • Accessibility
  • Disclaimer
  • Cookies
  • Contact Us

© 2023 NIHR Oxford Health Biomedical Research Centre · Log in